An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease

Trial Profile

An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kangstem Biotech
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
    • 01 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top